INS and hyperinsulinism: In a postmenopausal obesity-driven breast cancer model, TRF may increase systemic insulin sensitivity, reduce hyperinsulinemia, restore the diurnal gene expression rhythms in tumors, attenuate tumor growth and insulin signaling, and thereby inhibited tumor growth, delayed tumor initiation and reduced breast cancer metastasis to the lung [26].